Name | Number of supported studies | Average coverage | |
---|---|---|---|
pancreatic A cell | 4 studies | 98% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
pancreas | 4 studies | 59% ± 25% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 19054.29 | 327 / 328 | 78% | 1270.63 | 139 / 178 |
intestine | 55% | 703.48 | 535 / 966 | 24% | 61.73 | 125 / 527 |
prostate | 9% | 5.13 | 23 / 245 | 33% | 1.22 | 166 / 502 |
stomach | 19% | 16.71 | 68 / 359 | 17% | 14.84 | 48 / 286 |
bladder | 0% | 0 | 0 / 21 | 10% | 0.54 | 52 / 504 |
esophagus | 2% | 1.66 | 22 / 1445 | 3% | 0.23 | 6 / 183 |
lung | 1% | 0.39 | 3 / 578 | 4% | 2.02 | 42 / 1155 |
liver | 1% | 0.46 | 2 / 226 | 2% | 3.18 | 8 / 406 |
uterus | 0% | 0 | 0 / 170 | 3% | 0.14 | 13 / 459 |
breast | 2% | 1.90 | 10 / 459 | 0% | 0.24 | 5 / 1118 |
adrenal gland | 0% | 0.10 | 1 / 258 | 2% | 0.08 | 5 / 230 |
eye | 0% | 0 | 0 / 0 | 3% | 0.08 | 2 / 80 |
adipose | 2% | 6.42 | 20 / 1204 | 0% | 0 | 0 / 0 |
spleen | 2% | 7.79 | 4 / 241 | 0% | 0 | 0 / 0 |
ovary | 1% | 0.79 | 2 / 180 | 0% | 0.01 | 2 / 430 |
skin | 0% | 0.18 | 8 / 1809 | 1% | 0.34 | 4 / 472 |
brain | 1% | 0.54 | 21 / 2642 | 0% | 0.01 | 3 / 705 |
blood vessel | 1% | 1.28 | 16 / 1335 | 0% | 0 | 0 / 0 |
thymus | 1% | 0.52 | 5 / 653 | 0% | 0 | 0 / 605 |
peripheral blood | 1% | 0.35 | 7 / 929 | 0% | 0 | 0 / 0 |
heart | 1% | 0.28 | 5 / 861 | 0% | 0 | 0 / 0 |
kidney | 0% | 0 | 0 / 89 | 1% | 0.09 | 5 / 901 |
muscle | 0% | 0.04 | 1 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0050796 | Biological process | regulation of insulin secretion |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_1900118 | Biological process | negative regulation of execution phase of apoptosis |
GO_0007631 | Biological process | feeding behavior |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0010737 | Biological process | protein kinase A signaling |
GO_0014823 | Biological process | response to activity |
GO_0035774 | Biological process | positive regulation of insulin secretion involved in cellular response to glucose stimulus |
GO_0045722 | Biological process | positive regulation of gluconeogenesis |
GO_0007186 | Biological process | G protein-coupled receptor signaling pathway |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0006094 | Biological process | gluconeogenesis |
GO_0071377 | Biological process | cellular response to glucagon stimulus |
GO_0007189 | Biological process | adenylate cyclase-activating G protein-coupled receptor signaling pathway |
GO_0010800 | Biological process | positive regulation of peptidyl-threonine phosphorylation |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_0042593 | Biological process | glucose homeostasis |
GO_0090280 | Biological process | positive regulation of calcium ion import |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0034774 | Cellular component | secretory granule lumen |
GO_0005788 | Cellular component | endoplasmic reticulum lumen |
GO_0005179 | Molecular function | hormone activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0031769 | Molecular function | glucagon receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | GCG |
Protein name | Pro-glucagon [Cleaved into: Glicentin; Glicentin-related polypeptide (GRPP); Oxyntomodulin (OXM) (OXY); Glucagon; Glucagon-like peptide 1 (GLP-1) (Incretin hormone); Glucagon-like peptide 1(7-37) (GLP-1(7-37)); Glucagon-like peptide 1(7-36) (GLP-1(7-36)); Glucagon-like peptide 2 (GLP-2)] |
Synonyms | |
Description | FUNCTION: [Glucagon]: Plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. .; FUNCTION: [Glucagon-like peptide 1]: Potent stimulator of glucose-dependent insulin release. Also stimulates insulin release in response to IL6 . Plays important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Has growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis (Probable). .; FUNCTION: [Glucagon-like peptide 2]: Stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. .; FUNCTION: [Oxyntomodulin]: Significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. .; FUNCTION: [Glicentin]: May modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life. . |
Accessions | ENST00000375497.3 ENST00000418842.7 P01275 |